SS-31: The Peptide Protecting Your Cells' Power Plants

Mitochondria are not just batteries — they are elaborate, membrane bounded structures with an outer membrane, an intermembrane space, and a highly folded inner membrane where the actual energy production machinery is embedded. The electron transport chain — the system that converts food energy into ATP — sits in this inner membrane. The integrity of this membrane is essential to its function.

As cells age or experience chronic oxidative stress, the inner mitochondrial membrane becomes damaged. The tightly folded structure (called cristae) begins to unfold and flatten. The protein complexes of the electron transport chain become disorganized. Energy production efficiency drops. The mitochondria produces more oxidative byproducts and less ATP per unit of substrate metabolized.

This decline is not a single cause problem. It involves oxidative damage to membrane lipids, protein complex disassembly, reduced mitochondrial biogenesis, and accumulation of mitochondrial DNA mutations. But researchers studying which factor is most upstream found that damage to one specific lipid — cardiolipin — appeared to be a critical initiating event.

SS-31 (also known as Elamipretide in its clinical development form) is a synthetic tetrapeptide — four amino acids — designed with unusual chemical properties that allow it to cross multiple cellular membranes and concentrate specifically inside mitochondria. It was developed by Hazel Szeto and Peter Schiller at Weill Cornell Medical College — the SS in the name stands for Szeto-Schiller.

The 31 refers to its position in a library of related compounds synthesized during their research program. Early in the screening process, SS-31 showed the most potent mitochondria protective activity of any compound tested — orders of magnitude more potent than conventional antioxidants like vitamin E or CoQ10 at equivalent doses.

Elamipretide — the clinical name for SS-31 — has been in clinical trials for heart failure and rare mitochondrial diseases, giving it an emerging human safety and efficacy database alongside the extensive preclinical literature.

SS-31 works primarily by binding to cardiolipin — an unusual phospholipid (a fat based membrane component) found almost exclusively in the inner mitochondrial membrane. Cardiolipin is essential to the structure and function of the electron transport chain; the protein complexes that generate ATP are embedded in cardiolipin rich membrane regions and their function depends on the structural integrity of the cardiolipin around them.

When cardiolipin is oxidized by reactive oxygen species — which occurs continuously, and accelerates with age — it loses its structural properties. The electron transport chain complexes become disorganized. Mitochondrial membrane potential decreases. Energy production efficiency drops. SS-31 appears to stabilize and protect cardiolipin, preventing oxidation of this critical lipid and preserving the membrane architecture that energy production depends on.

This mechanism is distinct from broad antioxidants that simply neutralize reactive oxygen species generally. SS-31 concentrates at the specific site where the damage that matters most occurs — the cardiolipin in the inner mitochondrial membrane — and protects it specifically.

Heart failure is the most clinically advanced application. Elamipretide has completed Phase 2 trials for heart failure with reduced ejection fraction — a condition where the heart muscle does not pump effectively. Published trial data showed improvements in cardiac function measures. Phase 3 trials have been conducted, making this one of the most translatable research applications for any peptide in this catalog.

Kidney disease research has been another active area. Mitochondrial dysfunction is a key driver of renal tubular cell damage, and SS-31's targeted mitochondrial protection has been studied in multiple kidney disease models. Age related muscle loss (sarcopenia) represents a third application — muscle cells are among the most mitochondria dependent cells in the body, and their function declines significantly with mitochondrial dysfunction.

Barth syndrome — a rare X-linked genetic disease caused by defects in cardiolipin metabolism — is perhaps the most mechanistically direct application. SS-31 has received orphan drug designation for Barth syndrome. The research rationale is precise: the disease directly involves cardiolipin dysfunction, which is exactly what SS-31 was designed to address.

The mitochondrial targeting ability of SS-31 is what separates it from the large category of antioxidants. Most antioxidants — vitamins C and E, CoQ10, resveratrol — distribute throughout the body and neutralize reactive oxygen species wherever they encounter them. This broad distribution means very little of the administered dose reaches the specific mitochondrial sites where antioxidant protection matters most.

SS-31's chemistry allows it to concentrate in mitochondria at levels estimated to be hundreds to thousands of times higher than in the surrounding cytoplasm. This concentration creates antioxidant protection specifically where it is needed — at the inner membrane, around the electron transport chain, protecting cardiolipin from oxidative damage.

This targeting precision is what drives the dramatically greater potency observed with SS-31 compared to conventional antioxidants in published research. It is not simply a stronger antioxidant — it is an antioxidant precisely targeted to the site of most consequential oxidative damage.

Published preclinical research has used subcutaneous administration in most animal studies, with typical doses ranging from 0.5 to 5 milligrams per kilogram. Clinical trials in heart failure and kidney disease have used subcutaneous injection with daily administration over 1 to 4 week study periods.

Biomarker rich study designs are standard in SS-31 research — researchers measure mitochondrial function markers (oxygen consumption rate, ATP production capacity), oxidative stress markers (cardiolipin oxidation status, mitochondrial ROS levels), and functional outcomes (cardiac ejection fraction, kidney function markers) in parallel.

Given its clinical development context, researchers studying SS-31 have access to more rigorous human protocol designs than for most peptides — the clinical trial literature provides detailed administration protocols and monitoring approaches.

SS-31 is available for research with complete technical specifications. The molecular weight is 639.8 Da for the free acid form. The batch specific COA confirms sequence identity via mass spectrometry and HPLC purity — critical quality verification for a compound where potency depends on precise molecular structure.

SS-31 requires careful storage — lyophilized powder should be kept at -20°C for long term storage, with refrigeration acceptable for shorter periods. The product page details full storage requirements and reconstitution protocols for SS-31.

Researchers new to SS-31 typically start with the Szeto-Schiller original discovery papers before moving to the cardiac and mitochondrial aging literature, then to the Barth syndrome and kidney disease research.